
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is a fully integrated biotechnology company, utilizing various technologies to develop and commercialize pharmaceutical products, with strong focus on unmet medical needs. Their recent LTE study in NT1 and NT2 showed sustained efficacy and improvements in safety and potential future indications, supporting their currently undervalued stock price. The company has a strong pipeline, including ALKS 4510 and ALKS 7290, with potential updates later this year that could further boost their strong financial performance.
Bears say
Alkermes is at a disadvantage with their limited sales force for their only currently marketed product, and although their recent LTE data for an OX2R agonist looks promising, it has only been tested in a heterogenous population and still needs to undergo pivotal studies. Additionally, their management will need to dedicate more resources towards marketing and expanding their sales force in preparation for the launch of alixorexton and targeting both REMS certified and uncertified physicians.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares